Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs

Lauri E. Markowitz, Melanie Drolet, Norma Perez, Mark Jit, Marc Brisson

Article history:
Available online xxxx

Keywords:
Human papillomavirus vaccine
Vaccine effectiveness
Systematic review
HPV vaccine

1. Background

All three currently available human papillomavirus (HPV) vaccines were originally evaluated in clinical trials, licensed and recom-

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Corresponding author at: Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA, USA.
E-mail address: lem2@cdc.gov (L.E. Markowitz).

https://doi.org/10.1016/j.vaccine.2018.01.057
0264-410X/Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Please cite this article in press as: Markowitz LE et al. Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs. Vaccine (2018), https://doi.org/10.1016/j.vaccine.2018.01.057
and recommended a two-dose HPV vaccination schedule for girls starting the series at age 9 through 14 years [6]. In 2016, the Advisory Committee on Immunization Practices recommended a two-dose schedule in the United States for this age group [7]. Many countries in Europe, the Americas, and countries funded by Gavi, the Vaccine Alliance, either changed from a three-dose to a two-dose schedule in this age group, or introduced HPV vaccination with a two-dose schedule [8].

While immunogenicity trials have demonstrated non-inferiority of two HPV vaccine doses in young adolescents and were accepted by regulatory agencies, many effectiveness studies conducted in real world programs have largely shown lower effectiveness with fewer than three doses. We conducted a systematic review of the literature to: (1) summarize evidence about effectiveness of HPV vaccination by the number of doses, as measured in post-licensure studies, and (2) explore and discuss the main limitations and challenges of these studies.

2. Methods

2.1. Study selection

Studies were eligible if they fulfilled the following inclusion criteria: (1) reported effectiveness of HPV vaccination (bivalent or quadrivalent vaccine) on HPV infections, anogenital warts, or cervical abnormalities (based on cytological or histopathological results); (2) assessed effectiveness of HPV vaccination by the number of doses received (one, two, or three). We excluded studies if vaccine was administered as part of a randomized controlled trial (e.g., post hoc evaluations of clinical trials).

We searched Medline and Embase databases from January 1, 2007 to June 15, 2017 using a combination of Medical Subject Headings (MeSH) terms, title or abstract words, without restriction on the language of publications: (“papillomavirus vaccines”, “HPV vaccine”, “HPV vaccination”, “papillomavirus vaccine”, or “papillomavirus vaccination”) and (“program evaluation”, “immunization programs”, “population surveillance”, “sentinel surveillance”, “incidence”, “prevalence”, “rate”, “rates”, “effectiveness”, “doses”) and (“papillomavirus infections”, “HPV”, “uterine cervical neoplasms”, “cervical intraepithelial neoplasia”, “HPV related diseases”, “condylomata acuminata”, “genital warts”). The selection of eligible articles was performed independently by MD and NP on title and abstract first, and secondly on the full-text article.

2.2. Data extraction

Two authors (NP and LM) independently extracted the main study characteristics and outcomes using standardized forms. Any discrepancy between the two independent extractions was resolved by MD. The main study characteristics included the country, study design, age of study population at vaccination and outcome assessment, sample size according to the number of doses received, case definition, and statistical analyses (procedure used to assign the number of doses, and adjustment for potential confounders). Information on use of buffer periods (lag time between vaccination and counting of outcomes) was also collected. Buffer periods delay the case counting to attempt to exclude conditions caused by a prevalent infection at the time of vaccination.

Sources of bias in post-licensure studies examining the impact of HPV vaccination by number of doses include: (1) differences in the characteristics and age at vaccination between groups vaccinated with different number of doses; (2) likelihood of prevalent infection at vaccination; and (3) interval between the first and second dose of the HPV vaccine among two-dose vaccine recipients. Therefore, information on how authors dealt with these potential sources of bias was also extracted. Since one of the aims of this systematic review was to discuss the limitations of these studies, no studies were excluded on the basis of the methodological quality.

The main outcome was effectiveness of HPV vaccination comparing the incidence or prevalence of HPV-related endpoints between individuals vaccinated with different number of doses (three vs none, two vs none, one vs none, three vs two, three vs one, two vs one) of quadrivalent or bivalent vaccine. Results are presented as crude or adjusted risk ratios (RR) or odds ratios (OR). Of note, because eligible studies used different buffer periods or age groups at vaccination and at outcome assessment, it was not possible to pool results from the studies.

3. Results

The literature search identified 3787 articles, from which 26 full articles were assessed. After reading full texts, 12 articles were excluded, leaving 14 in our review (Fig. 1) [9–22]. These publications were from eight different countries, published from 2013 through 2017: Australia (three), Scotland (three), United States (two), Sweden (two), and one each from Belgium, Canada, Denmark, and Spain (Table 1). All evaluations were conducted within the context of a recommended three-dose schedule of either bivalent HPV vaccine (three) or quadrivalent HPV vaccine (eleven). Articles included analyses of effectiveness for prevention of HPV infection (two), anogenital warts (six), and cervical cytological or histological abnormalities (six) (Table 2 and Appendix).

Recognizing the potential for confounding, all investigators attempted to control for or stratified by potentially important variables, such as age at vaccination; however, limited other variables were available in most studies (Table 1). Four studies also evaluated the impact of different buffer periods and four evaluated different intervals between doses for two-dose vaccine recipients.

3.1. HPV prevalence

The two studies that reported vaccine effectiveness for reduction of prevalent vaccine type infection (HPV 16 or 18) were both from Scotland, conducted in the context of a three-dose bivalent HPV vaccination program that had achieved high coverage in the routine and catchup target age groups. The studies used residual cervical screening samples obtained at first screen of 20–21 year-olds and national vaccine registry data. Most two-dose vaccine recipients received doses at a one-month interval. Kavanagh et al. found statistically significant effectiveness for three doses, aOR = 0.43 (95% CI 0.34, 0.55); but not two doses, aOR = 0.68 (95% CI 0.42, 1.12); or one dose, aOR = 0.95 (95% CI 0.51, 1.76) [9]. There were few one- or two-dose vaccine recipients. In the second study, Cuschieri et al. over-selected women partially vaccinated [10]. Compared with three-dose vaccine recipients, partially vaccinated women were older than those fully vaccinated and differed by socioeconomic status. Statistically significant effectiveness was found for three doses, aOR = 0.27 (95% CI 0.28, 0.37); two doses, aOR = 0.45 (95% CI 0.29, 0.69); and one dose, aOR = 0.52 (95% CI 0.31, 0.83). Neither study performed a formal comparison of effectiveness of three doses vs fewer doses; confidence intervals for the effectiveness estimates of three, two and one dose(s) overlapped.

3.2. Anogenital warts

The six evaluations of anogenital wart outcomes were retrospective cohort studies from five different countries that had introduced quadrivalent HPV vaccination [11–16]. Only one study presented characteristics of women by number of doses [12]
although all studies adjusted analyses for age at vaccination and some were able to adjust for educational level or markers of socioeconomic status (Table 1). Most two-dose vaccine recipients received doses separated by two months. Two studies also included assessment of different buffer periods [11,14] and three included assessment of different intervals between doses in two-dose vaccine recipients [12,14,16].

Herweijer et al. evaluated vaccine effectiveness in Sweden using data from national registries. The population evaluated included girls and women vaccinated during a time of opportunistic vaccination before HPV vaccination was incorporated into the routine school-based program [11]. In the primary analyses, a three-month buffer period was used before anogenital wart counting. The effect of different buffer periods was examined and analyses were stratified by age at vaccination (10–16 years and 17–19 years) and adjusted for attained age and parental education. There was statistically significant effectiveness for three doses, aRR = 0.20 (95% CI 0.17, 0.23); two doses, aRR = 0.32 (95% CI 0.26, 0.40); and one dose, aRR = 0.54 (95% CI 0.43, 0.68). Vaccine effectiveness was significantly higher for three compared with two or one dose(s). However, there was no statistically significant difference between two and three doses within a four-month period, regardless of the age at vaccine initiation.

In a study conducted in Denmark using data from national registries, Blomberg et al. evaluated vaccine effectiveness among girls and women vaccinated as part of a routine and catchup program. Statistically significant effectiveness was found for one compared with no dose, RR = 0.51 (95% CI 0.46, 0.56). Data were not reported for effectiveness of three and two doses compared with no dose, but the investigators found that anogenital warts occurred significantly less frequently with each additional dose: two vs one, RR = 0.44 (95% CI 0.37, 0.51); three vs two, RR = 0.46 (95% CI 0.39, 0.54) [12]. After adjustment for age at vaccination, maternal educational level and income, and calendar time, effectiveness for three doses remained significantly higher than for two doses. However, there was no statistically significant difference between three and two doses with an interval > four months between doses; the RR was close to one with an interval of six months. This change in effectiveness for three compared with two doses, with increasing interval between doses, was observed for women who initiated vaccination at age <16 years and ≥16 years.

Somewhat similar findings related to the effect of interval between two doses were reported by Lamb et al. who examined effectiveness of three compared with two doses using data from Swedish national registries [16]. Higher effectiveness was observed for three compared with two doses, when two doses were admin-
| Endpoint/vaccine/ reference | Country | Study design | Study population Age (years) at Vaccination N by dose number | Case definition | Statistical analyses | Assignment of dose number | Buffer periods (months) | Adjustment or stratification |
|----------------------------|---------|--------------|---------------------------------------------------------------|-----------------|---------------------|-------------------------|-------------------------|--------------------------|
| **HPV prevalence**         |         |              |                                                                |                 |                     |                         |                         |                          |
| Bivalent vaccine           |         |              |                                                                |                 |                     |                         |                         |                          |
| Kavanagh et al. (2014)     | Scotland| Cross-sectional study using screening registry data          | 15–17 20–21 0: 3418 1: 55 2: 106 3: 1100 | HPV 16 or 18 DNA positivity in liquid based cytology samples | Final status 0 | Birth year cohort, deprivation score |                         |                         |                          |
| Cuschieri et al. (2016)    | Scotland| Cross-sectional study using screening registry data with additional sampling of women with < 3 doses | 15–17 20–21 0: 3619 1: 177 2: 300 3: 1853 | HPV 16 or 18 DNA positivity in liquid based cytology samples | Final status 0 | Birth year cohort, deprivation score, age at first dose |                         |                         |                          |
| **Anogenital warts**       |         |              |                                                                |                 |                     |                         |                         |                          |
| Quadrivalent vaccine       |         |              |                                                                |                 |                     |                         |                         |                          |
| Herweijer et al. (2014)    | Sweden  | Retrospective cohort study using population-based health registries | 10–19 10–24 0: 926,119 1: 115,197 2: 107,338 3: 89,836 | First observed diagnosis: ICD-10 code A63.0 or podophyllotoxin/imiquimod prescription | Time-dependent Final status 0 | Age at first vaccination, at outcome, parental education | 0 to 12 | Age at first dose |                          |
| Blomberg et al. (2015)     | Denmark | Retrospective cohort study using population-based health national registries | 12–27 12–27 0: 188,956 1: 55,666 2: 93,519 3: 212,549 | First diagnosis: ICD-10 code A63.0 or podophyllotoxin prescription | Time-dependent | Age at vaccination, maternal education disposable income, calendar year | 1 | Age at first dose |                          |
| Dominia-Felden et al. (2015)| Belgium| Retrospective cohort study using sick-fund/insurance data | 10–23 16–23 0: 63,180 1: 4020 2: 3587 3: 35,792 | First prescription of imiquimod and reimbursement | Time-dependent | | 1 | Age at first dose |                          |
| Perkins et al. (2017)      | United States | Retrospective cohort study using commercial claims database | 9–25 9–25 0: 201,933 1: 30,438 2: 36,583 3: 118,962 | ICD-9 codes | Final status 0, 12 | Age, regions, SES indicators, calendar year, differential observation periods |                         |                         |                          |
| Navarro-Illana et al. (2017)| Spain | Retrospective cohort study using national registries | 14 14–19 0: NA 1: NA 2: NA 3: NA | First diagnosis of ICD-9-CM code 078.11 | Time-dependent | Age, calendar year, health department | 0 | Age at outcome, time between doses |                          |
| Lamb et al. (2017)         | Sweden  | Retrospective cohort study using national registries | 10–19 10–27 2: 79,042 3: 185,456 | First diagnosis of ICD-10 code A63.0 or podophyllotoxin/imiquimod prescription | Time-dependent | | 0 | Age at outcome, time between doses |                          |
| **Cervical abnormalities** |         |              |                                                                |                 |                     |                         |                         |                          |
| Quadrivalent vaccine       |         |              |                                                                |                 |                     |                         |                         |                          |
| Gertig et al. (2013)       | Australia| Retrospective cohort study using linked data from registries | 12–19 12–21 0: 14,085 1: 1422 2: 2268 3: 21,151 | Histology: CIN3/AIS, CIN2, CIN1, any high grade Cytology: low grade and high grade | Time-dependent Final status | Age at first screen, remoteness area, SES | 0 | Year of birth, remoteness area, SES, follow-up time |                          |
| Crowe et al. (2014)        | Australia| Case control study using linked data from registries | 12–26 11–31 0: 53,761 1: 9649 2: 10,950 3: 23,106 | Histology: CIN2+/AIS | Final status 0, 1, 6, 12 | Year of birth, remoteness area, SES, follow-up time |                         |                         |                          |
| Country            | Study design                                      | Age (years) at Vaccination | Age (years) at Outcome | N by dose number | Case definition                                      | Statistical analyses                                      | Assignment of dose number | Buffer periods (months) | Adjustment or stratification                      |
|--------------------|---------------------------------------------------|----------------------------|------------------------|------------------|------------------------------------------------------|----------------------------------------------------------|--------------------------|------------------------|-----------------------------------------------------|
| Australia          | Retrospective cohort study using linked regional data registries | 12–26                     | 12–30                  | 0: 133,055       | 1: 20,659                                            | Final status: 0, 1, 6, 12, 24                             | Age, remoteness, SES, screening start (before or after vaccination) |
| United States      | Retrospective cohort study using medical center records | 11–20                     | 11–27                  | 0: 1632          | 1: 695                                               | Final status: 1                                           | Age, insurance, language, clinic type, CT screening, and baseline cytology |
| Canada             | Nested case-control study using linked data from registries | 10–15                     | 18–21                  | 0: 5712          | 1: 327                                               | Final status: 0                                           | Age, urban/rural, neighborhood income                      |
| Scotland           | Retrospective cohort study using linked national registry data | 15–17                     | 20–21                  | 0: 75,113        | 1: 1315                                              | Final status: 0                                           | Age, birth year cohort year, deprivation score             |

Abbreviations: CT, chlamydia; SES, socioeconomic status; CIN, cervical intraepithelial neoplasia; CIN2+, CIN grade 2 or worse; AIS, adenocarcinoma in situ; ICD-9, International Classification of Disease, ninth revision; NA, not available

- Buffer period is the lag time between vaccination and counting of outcomes.
- By multimetric HPV assay detecting 24 types including all established high risk types.
- By Optiplex HPV assay detecting 24 types including all established high risk types.
- Three possible scenarios: (a) ≥1 diagnosis of ICD-9 code 078.1; (b) ≥1 diagnosis of ICD-9 code 078.1, 078.10, 078.19 plus destruction/excision procedure or ICD-9 code 211.4, 216.5, 221.8, 222.9; (c) ≥1 prescription for anogenital warts plus destruction/excision procedure or ICD-9 code 211.4, 216.5, 221.8, 222.9.
- Presented as person-years in this article.
- Low-grade cytology defined as atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. High-grade cytology defined as atypical squamous cells, cannot rule out a high-grade lesion, or high-grade squamous intraepithelial lesion.
- High-grade cytology defined as possible high-grade squamous intraepithelial lesion (HSIL), HSIL, HSIL with possible microinvasion/invasion, squamous cell carcinoma, possible high-grade endocervical glandular lesion, AIS, AIS with possible microinvasion/invasion and adenocarcinoma. Low-grade cytology defined as possible low-grade squamous intraepithelial lesions (LSIL), LSIL and atypical endocervical cells of uncertain significance.
Table 2

Studies that evaluated HPV vaccine effectiveness by number of doses: analyses and main findings.

| Endpoint/vaccine reference | Study population | Buffer (months) | Sensitivity analyses by age group/buffer/dose interval | Formal comparison of 3 vs 2 or 1 doses | Main findings |
|----------------------------|------------------|----------------|------------------------------------------------------|---------------------------------------|---------------|
| **HPV prevalence**         |                  |                |                                                      |                                       |               |
| Bivalent vaccine           |                  |                |                                                      |                                       |               |
| Kavanagh et al. (2014)     | 15–17            | 20–21          | 0                                                    | Yes/No/No                             | No            |
|                            |                   |                |                                                      |                                       |               |
|                            |                   |                |                                                      |                                       |               |
| Cuschieri et al. (2016)    | 15–17            | 20–21          | 0                                                    | No/No/No                              | No            |
|                            |                   |                |                                                      |                                       |               |
|                            |                   |                |                                                      |                                       |               |
| Quadrivalent vaccine       |                  |                |                                                      |                                       |               |
| Herweijer et al. (2014)    | 10–19            | 10–24          | 3                                                    | Yes/Yes/No                            | Yes           |
|                            |                   |                |                                                      |                                       |               |
|                            |                   |                |                                                      |                                       |               |
| Blomberg et al. (2015)     | 12–27            | 12–27          | 1                                                    | Yes/No/Yes                            | Yes           |
|                            |                   |                |                                                      |                                       |               |
|                            |                   |                |                                                      |                                       |               |
| Dominik-Felden et al. (2015)| 10–23         | 16–23          | 1                                                    | No/No/No                              | No            |
|                            |                   |                |                                                      |                                       |               |
|                            |                   |                |                                                      |                                       |               |
| Perkins et al. (2017)      | 9–25             | 9–25           | 0                                                    | No/Yes/Yes                            | Yes           |
|                            |                   |                |                                                      |                                       |               |
|                            |                   |                |                                                      |                                       |               |
| Navarro-Illana et al. (2017)| 14              | 14–19          | 0                                                    | No/No/No                              | No            |
|                            |                   |                |                                                      |                                       |               |
|                            |                   |                |                                                      |                                       |               |
| Lamb et al. (2017)         | 10–19            | 10–27          | 0                                                    | Yes/No/Yes                            | Yes           |
|                            |                   |                |                                                      |                                       |               |
|                            |                   |                |                                                      |                                       |               |
| Cervical abnormalities     |                  |                |                                                      |                                       |               |
| Quadrivalent vaccine       |                  |                |                                                      |                                       |               |
| Gertig et al. (2013)       | 12–19            | 12–21          | 0                                                    | No/No/No                              | No            |
|                            |                   |                |                                                      |                                       |               |
|                            |                   |                |                                                      |                                       |               |

*Statistically significant effectiveness for 3, but not 2 or 1 doses compared to 0*  
3: aRR = .43 (CI .34, .55); 2: aRR = .68 (CI .42, 1.12); 1: aRR = .95 (CI .51, 1.76)  
Effectiveness CI overlap for 3, 2 and 1 doses  
Similar results when stratified by age at vaccination  
Statistically significant effectiveness for 3, 2, and 1 doses compared to 0  
3: aOR = .27 (CI .20, .37); 2: aOR = .45 (CI .29, .69); 1: aOR = .52 (CI .31, .83)  
Effectiveness CI overlap for 3, 2 and 1 doses  
Statistically significant effectiveness for 3, 2, and 1 doses compared to 0  
3: aRR = .20 (CI .17, .23); 2: aRR = .32 (CI .26, .40); 1: aRR = .54 (CI .43, .68)  
Effectiveness CI overlap for 3, 2 and 1 doses  
Significantly higher effectiveness of 3 compared to 2 and 1 doses  
With buffer periods > 4 months, no significant difference between 3 and 2 doses  
Effectiveness CI overlap for 3, 2 and 1 doses  
Significantly higher effectiveness of 3 compared to 0 dose, RR = .51 (CI .46, .56)  
Effectiveness not reported for 3 and 2 doses compared to 0  
Effectiveness significantly increased with each dose: RR 2 vs 1 dose = .44 (CI .37, .51); RR 3 vs 2 doses = .46 (CI .39, .54)  
With dose interval > 4 months, no significant difference between 3 and 2 doses  
Effectiveness CI overlap for 3 and 1 doses  
No overlap for 3 and 1 doses  
Statistically significant effectiveness for 3 doses compared to 0, aRR = .52 (CI .46,.60)  
Effectiveness not reported for 2 and 1 doses compared to 0  
Higher effectiveness for 3 compared with 1 doses, aRR = .82 (CI .71, .95); but no significant difference between 3 and 2 doses, aRR = .89 (CI .78, 1.03)  
Statistically significant effectiveness for 3, 2, and 1 doses compared to 0  
3: aOR = .53 (CI .36, .77); 2: aOR = .87 (CI .46, 1.67); 1: aOR = 1.40 (CI .75, 2.61)  
Effectiveness CI overlap for 3, 2 and 1 doses  
Statistically significant effectiveness for 3, 2, and 1 doses compared to 0  
3: aOR = .53 (CI .36, .77); 2: aOR = .87 (CI .46, 1.67); 1: aOR = 1.40 (CI .75, 2.61)  
Effectiveness CI overlap for 3, 2 and 1 doses  
Statistically significant effectiveness for 3, 2, and 1 doses compared to 0  
3: aOR = .53 (CI .36, .77); 2: aOR = .87 (CI .46, 1.67); 1: aOR = 1.40 (CI .75, 2.61)  
Effectiveness CI overlap for 3, 2 and 1 doses  
Similar results when stratified by age at vaccination

Outcome summarized: CIN3/AIDS

Please cite this article in press as: Markowitz LE et al. Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs. Vaccine (2018), https://doi.org/10.1016/j.vaccine.2018.01.057
| Endpoint/vaccine/ reference | Study population Age (years) at Vaccination | Buffer* (months) | Sensitivity analyses by age group/buffer/dose interval* | Formal comparison of 3 vs 2 or 1 doses | Main findings |
|-----------------------------|---------------------------------------------|------------------|--------------------------------------------------|----------------------------------------|---------------|
|                             |                                             |                  |                                                  |                                        |               |
|                             |                                             |                  | 0                                                | Yes/Yes/No                             | No            |
|                 Crowe et al. (2014) [18] | 12–26                                      | 11–31            |                                                  |                                        |               |
|                             |                                             |                  |                                                  |                                        |               |
|                             |                                             |                  |                                                  |                                        |               |
|                 Brotherton et al. (2015) [19] | 12–26                                      | 12–30            |                                                  | 0 Yes/Yes/Yes                           | No            |
|                             |                                             |                  |                                                  |                                        |               |
|                             |                                             |                  |                                                  |                                        |               |
|                 Hofstetter et al. (2016) [20] | 11–20                                      | 11–27            |                                                  | 1 Yes/No/No                             | No            |
|                             |                                             |                  |                                                  |                                        |               |
|                             |                                             |                  |                                                  |                                        |               |
|                 Kim et al. (2016) [21] | 10–15                                      | 18–21            |                                                  | 0 No/No/No                             | No            |
|                             |                                             |                  |                                                  |                                        |               |
|                             |                                             |                  |                                                  |                                        |               |
|                 Bivalent vaccine Pollock et al. (2014) [22] | 15–17                                      | 20–21            |                                                  | 0 No/No/No                             | No            |
|                             |                                             |                  |                                                  |                                        |               |
|                             |                                             |                  |                                                  |                                        |               |

**Outcome summarized:**
- High grade histological lesions
- Statistically significant effectiveness for 3 and 2 doses, but not 1 compared to 0
  - 3: \( \text{aOR} = .54 \) (CI .43, .67); 2: \( \text{aOR} = .79 \) (CI .64, .98); 1: \( \text{aOR} = .95 \) (CI .77, 1.16)
- Effectiveness CI overlap for 3 and 2 doses, no overlap for 3 and 1 doses
- Buffer periods from 1 to 12 months - no consistent impact on 3, 2 and 1 dose effectiveness estimates
- Similar results when stratified by age at vaccination

**Outcome summarized:**
- CIN3/AIS
- Statistically significant effectiveness for 3, but not 2 and 1 doses compared to 0
  - 3: \( \text{aRR} = .69 \) (CI .58, .81); 2: \( \text{aRR} = 1.17 \) (CI .92, 1.48); 1: \( \text{aRR} = 1.41 \) (CI 1.12, 1.77)
- Effectiveness CI for 3, 2 and 1 doses do not overlap
- With increasing buffer periods, some effectiveness for 2 and 1 doses in several age groups
- No difference in effectiveness by interval between 2 doses
- Similar results when stratified by age at vaccination

**Outcome summarized:**
- Any abnormal cytology
- Statistically significant effectiveness for 3 and 2, but not 1 dose compared to 0
  - 3: \( \text{aRR} = .58 \) (CI .48, .69); 2: \( \text{aRR} = .81 \) (CI .66, .95); 1: \( \text{aRR} = 1.05 \) (CI .88, 1.26)
- Effectiveness CI overlap for 3, 2 and 1 doses
- Similar results when stratified by age at vaccination, although effectiveness of 2 doses compared to 0 not always significant

**Outcome summarized:**
- High grade cytology
- Statistically significant effectiveness for 3, but not 2 and 1 doses compared to 0
  - 3: \( \text{aOR} = .48 \) (CI .28, .81); 2: \( \text{aOR} = .77 \) (CI .49, 1.21); 1: \( \text{aOR} = .45 \) (CI .11, 1.83)
- Effectiveness CI overlap for 3, 2 and 1 doses

**Outcome summarized:**
- CIN3
- Statistically significant effectiveness for 3, but not 2 and 1 doses compared to 0
  - 3: \( \text{aRR} = .45 \) (CI .35, .58); 2: \( \text{aRR} = .77 \) (CI .49, 1.21); 1: \( \text{aRR} = 1.42 \) (CI .89, 2.28)
- Effectiveness CI overlap for 3 and 2 doses, no overlap for 3 and 1 doses

**Abbreviations:** RR, relative risk; aRR, adjusted RR; aOR, adjusted odds ratio; CI, 95% confidence intervals; CIN3, cervical intraepithelial neoplasia grade 3; AIS, adenocarcinoma in situ

* Buffer period is the lag time between vaccination and counting of outcomes. This column shows buffer period in main analysis.

* Interval between doses for 2-dose vaccine recipients.

* Several outcomes were presented in some articles for cervical cytological or histological abnormalities. We summarized results for the outcome most proximal to cervical cancer.
stered 0–3 months apart, but not when the interval was 4–7 months. Effectiveness of three, two or one doses compared with no dose was not reported.

A study using a commercially available claims database in the United States determined vaccine effectiveness among girls continuously enrolled since January 2007 [14]. For three doses compared with no dose, the aRR was 0.52 (95% CI 0.46, 0.60). Data were not reported for one or two doses compared with no dose. While higher effectiveness was found for three doses compared with one dose, aRR = 0.82 (95% CI 0.71, 0.95), the difference between three and two doses, aRR = 0.89 (95% CI 0.78, 1.03), did not reach statistical significance. In the main analysis, exposure time was counted starting after the last dose; reported findings did not change when a one year buffer period was used. The study also examined interval between doses. Among two-dose vaccine recipients, there was no difference in incidence among those who received doses at an interval of <5 months or ≥5 months.

In a study from Belgium, using an insurance database, statistically significant effectiveness was found for three doses, aRR = 0.12 (95% CI 0.07, 0.21); and two doses, aRR = 0.34 (95% CI 0.14, 0.83); but for one dose, aRR = 0.63 (95% CI 0.35, 1.16) [13]. There was no formal statistical comparison of three vs fewer doses; confidence intervals of three and two dose effectiveness overlapped.

In Spain, quadrivalent HPV vaccine was used for only two years, and in a narrowly focused target age group, before switching to bivalent HPV vaccine. In an effectiveness study, quadrivalent vaccine recipients had initiated vaccination at age 14 years [15]. Compared with no dose, statistically significant effectiveness was reported for three, aRR = 0.24 (95% CI 0.15, 0.34); two, aRR = 0.36 (95% CI 0.14, 0.68); and one dose, aRR = 0.39 (95% CI 0.13, 0.80). There was no formal statistical comparison of three vs fewer doses. The confidence intervals for three, two, and one dose effectiveness estimates overlapped. There were few anogenital wart diagnoses in one- and two-dose vaccine recipients, precluding evaluation of different buffer periods or varying time between two doses. However, while case counting started after the last dose, time between the last dose and first genital wart diagnosis was at least one year in all but one case.

In summary, among six studies evaluating quadrivalent HPV vaccine effectiveness for prevention of anogenital warts, four included a comparison of three, two and one doses with no dose; all found highest effectiveness with three doses, and lower but significant effectiveness with two doses. Three of the four studies found significant effectiveness with one dose [11,12,15]. Four studies also formally compared three and two doses, finding either no significant difference in the primary analysis or in analyses with different buffer periods or two-dose intervals [11,12,14,16]. Two studies examined different buffer periods; a longer buffer period decreased differences in effectiveness between three and two doses in one study [11]. In the three studies that explored intervals between doses in two-dose vaccine recipients [12,14,16] one found no difference between three doses and two doses with an interval longer than four months [12]. Another study found that effectiveness of two doses administered at a four to seven month interval was similar to the standard three-dose schedule [16].

Of note, two studies were able to examine impact of bivalent HPV vaccine, because both bivalent and quadrivalent HPV vaccines had been used in the countries (Spain and Belgium) [13,15]. No reduction in anogenital warts was observed after bivalent vaccination in either study.

3.3. Cervical cytological histological abnormalities

Six studies evaluated vaccine effectiveness for prevention of cervical cytological or histological abnormalities, including five for quadrivalent vaccine and one for bivalent vaccine. Outcomes assessed were based on histology only (two), cytology only (two), and both cytology and histology (two). Histological abnormalities evaluated included cervical intraepithelial neoplasia (CIN) grade 1, 2 and 3 or CIN2+ (CIN grade 2 or worse or adenocarcinoma in situ [AIS]) and CIN3/AIS. All studies described characteristics of women by number of doses, with most reporting some differences, particularly for age at first vaccine dose; all adjusted analyses for age at vaccination as well as limited other characteristics (Table 1).

Three of the four studies evaluating abnormal histology were conducted in Australia, a country that had achieved high vaccination coverage in routine and catchup age groups [17–19]. Two studies included women vaccinated at a wide age range and stratified results by age at first vaccination [18,19]. In a retrospective cohort study, statistically significant effectiveness against CIN3/AIS was observed for three doses, aRR = 0.53 (95% CI 0.36, 0.77), but not for two doses, aRR = 0.87 (95% CI 0.46, 1.67), or one dose, aRR = 1.40 (95% CI 0.75, 2.61) [17]. There was no formal statistical comparison of three vs fewer doses. Results were similar for any high grade lesion. The second study was a nested case-control study [18]. Statistically significant effectiveness was reported for prevention of high grade histological lesions for three doses, aOR = 0.54 (95% CI 0.43, 0.67), and for two doses, aOR = 0.79 (95% CI 0.64, 0.98), but not for one dose, aOR = 0.95 (95% CI 0.77, 1.16). There was no formal statistical comparison of three vs fewer doses.

The results were generally similar when stratified by age at vaccination. A buffer period of 1 to 12 months had little impact on three-dose vaccine effectiveness estimates but increased estimates in some age strata for one and two doses (Appendix).

In the third study from Australia, Brotherton et al. assessed effectiveness against cervical histological and cytological abnormalities, including varying buffer periods and also stratified by vaccination before or after the first cervical cancer screen [19]. Among women vaccinated before their first screen, there was statistically significant effectiveness against CIN3/AIS for three doses compared with no dose, aRR = 0.69 (95% CI 0.58, 0.81), but not for two doses, aRR = 1.17 (95% CI 0.92, 1.48), or one dose, aRR = 1.41 (1.12, 1.77). With increasing length of buffer period, some effectiveness for two and one doses in several age groups was observed (Appendix). There was no difference in effectiveness of two doses with an interval of >6 months vs <6 months, regardless of the buffer period.

The one study that evaluated histological abnormalities after bivalent vaccine was conducted in Scotland [22]. Three-dose bivalent vaccine recipients had a lower risk of CIN3 compared with those unvaccinated, aRR = 0.45 (95% CI 0.35, 0.58). There was no significant effectiveness after two doses, aRR = 0.77 (95% CI 0.49, 1.21) or 1 dose, aRR = 1.42 (95% CI 0.89, 2.28). There was no formal statistical comparison of three vs fewer doses.

Two studies exclusively evaluated cervical cytological outcomes. Hofstetter et al. evaluated reduction in any cervical cytological abnormality among women at U.S. community health clinics using data from medical systems registries [20]. For those vaccinated at age 11–20 years, statistically significant effectiveness was observed for three doses, aRR = 0.58 (95% CI 0.48, 0.69), and two doses, aRR = 0.81 (95% CI 0.66, 0.99), but not one dose, aRR = 1.05 (95% CI 0.88, 1.26). There was no formal statistical comparison of three vs fewer doses. Point estimates of effectiveness varied by age at vaccination but the findings by number of doses were generally similar. In a study from Canada, Kim et al. presented any, low grade, and high grade abnormal cytology results respectively [21]. While point estimates varied by outcome, the results were similar in that statistically significant effectiveness was found only with three doses. For high grade cytological abnormalities results were: three doses, aOR = 0.48 (95% CI 0.28, 0.81); two doses, aOR = 0.17 (95% CI 0.02, 1.20); and one dose, aOR = 0.45 (95% CI

Please cite this article in press as: Markowitz LE et al. Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs. Vaccine (2018), https://doi.org/10.1016/j.vaccine.2018.01.057
In summary, among six studies evaluating vaccine effectiveness for prevention of cervical cytological (four) or histological abnormalities (four), all found effectiveness for three doses. Women who received less than three doses were different than three-dose vaccine recipients in many studies, and investigators conducted stratified and/or adjusted analysis to control for these differences. Four studies found some effectiveness for prevention of high grade histological abnormalities with two doses, and two studies found effectiveness with one dose, in some age groups, in analyses with longer buffer periods [18,19]. Most two-dose vaccine recipients received two doses at a one- or two-month interval. A longer interval between two doses had no impact on the effectiveness estimate in the one study that examined this [19].

4. Discussion

In this systematic review of HPV vaccine effectiveness by number of doses, most of the 14 studies found the highest point estimate of effectiveness with three doses, followed by two doses, and one dose. However, few studies directly compared three, two and one dose(s) and some effectiveness estimates had wide confidence intervals due to the small number of outcomes in one- and two-dose vaccine recipients. All found statistically significant effectiveness for three doses and 11 studies found effectiveness for two doses [10–20]. In six studies significant effectiveness was observed for one dose in some analyses [10–12,15,17,19].

Variation in effectiveness by number of doses was observed across all endpoints (prevalence, anogenital warts and cervical abnormalities). There were generally consistent findings regarding buffer periods in the studies that evaluated this, with three of four studies finding higher effectiveness estimates for one and two doses and a decrease in the differences by number of doses with longer buffer periods. Among studies presenting results stratified by age group, higher effectiveness estimates were generally found with younger age at vaccination, although the differences were not formally tested. There were differences in the impact of varying time interval between two doses. Two studies of anogenital warts found higher two-dose effectiveness with increasing interval through six or seven months [11,16]. The one study of cervical abnormalities that evaluated interval between two doses did not find a difference [19].

Findings in these studies are, in large part, different from what might be expected based on immunogenicity trials which showed non-inferiority of two compared with three doses, and other studies which suggest efficacy with a single dose. However, there are several important caveats that need to be considered when interpreting the findings. Firstly, the post-licensure studies were all conducted in settings of a national three-dose recommendation and girls who received one or two doses differed from those completing the recommended schedule. Most of the studies included girls who were vaccinated beyond the routine target age group, in the early years of the vaccination programs when catch-up programs had been implemented. In several studies, fewer than three-dose vaccine recipients were older than three-dose vaccine recipients at the time of vaccination, had lower socio-economic status, and/or had indicators of earlier sexual exposure (e.g., younger cervical screening, vaccination at a family planning clinic, screening for a sexually transmitted infection). Thus, girls who received fewer doses were at higher risk of HPV infection, which biases results towards a greater effectiveness of three doses compared to one or two doses. Although most studies adjusted analyses for some risk factors, it is likely that residual confounding remained.

Secondly, in retrospective studies it is impossible to identify individuals who were already infected with HPV at the time of vaccination. The proportion of individuals already infected increases with older age at vaccination. Since girls vaccinated with one or two doses in the studies were often older when vaccinated and had indicators of earlier sexual exposure, prevalent infections at the time of vaccination would bias towards lower vaccine effectiveness of one and two doses (compared with three doses). To overcome the problem of prevalent infections, some researchers introduced buffer periods in their analyses, which delay case counting to exclude conditions caused by a prevalent infection. In Herweijer et al. the effectiveness of one dose compared to no vaccination increased with increasing buffer period and the difference between the effectiveness of three and two doses decreased [11]. With a buffer period of one month, the effectiveness of one dose compared to no vaccination increased to 28%, and to >50% with buffer periods > four months. Brotherton et al. also evaluated different buffer periods in a study of effectiveness for cervical lesions, showing that effectiveness increased with longer buffer periods [19]. One study of genital warts reported no effect of buffer periods, although data were not shown [14].

Longer buffer periods might be more helpful for evaluation of vaccine effectiveness against cervical high grade histological abnormalities than anogenital warts, since the former take more time to develop after infection [22]. In addition, buffer periods could be of greater importance based on age at vaccination. Therefore, the impact of buffer periods could vary across studies. While ideally buffer periods should be explored for effectiveness studies, they reduce the number of person-years with one or two doses, which is generally small in post-licensure studies; this results in low statistical power (i.e., insufficient power to detect statistically significant differences in effectiveness between one, two and three doses).

Thirdly, since all post-licensure studies published to date were conducted in settings of a national three-dose recommendation, most individuals vaccinated with two doses had received doses at a 0–1 month or 0–2 month interval, as recommended with a three-dose schedule. However, immunogenicity studies have found non-inferior results with two doses compared to three doses when the two doses were separated by about six months [3–5]. The longer interval is thought to allow maturation of B cells and the second vaccination to act as a booster dose. Results of the immunogenicity studies led to the recommendation for a two-dose schedule (administered at 0, 6–12 months) for females aged 9 through 14 years old at the time of their first dose [6,7]. Although the number of girls vaccinated with two doses separated by at least six months was small in the post-licensure studies identified, four studies evaluated interval between doses [12,14,16,19]. Blomberg et al. found that as the time between dose one and two increased from two to six months, the difference in effectiveness between two and three doses decreased; with an interval of >four months there was no difference [12]. However, two studies in this review did not find that varying intervals between two doses had that same effect [14,19]. It is possible that the finding of higher effectiveness with a longer interval between two doses in these observational studies is the result of the longer interval acting as a buffer period and is not related to the spacing between doses. If so, the inconsistent findings by interval between doses could be due to differing importance of buffer periods for the endpoints and age groups evaluated.

Finally, as in all vaccine effectiveness studies, the accuracy of vaccine history is important. Assessment of vaccination status can be more challenging for HPV than for other vaccine preventable diseases, as the outcomes generally occurs years after...
vaccination and because vaccine registries in some countries do not include adolescent vaccinations. Most studies included in this review were conducted in countries with national vaccine registries. However, underreporting of vaccinations to registries can still occur [18,19]. In studies using claims or insurance data, particularly in the United States, vaccination history could be incomplete if girls moved or changed insurers during the vaccination series. Incomplete vaccination histories could lead to overestimating effectiveness of fewer than three doses.

In conclusion, most post-licensure studies examining HPV vaccine effectiveness by number of doses report highest effectiveness with three doses, but some found no statistically significant difference between two and three doses. Additionally, almost half of the studies found some effectiveness for one dose. Several biases in currently available data impact estimates, with most biasing two- and one-dose results away from showing effectiveness. Future studies of real-world HPV vaccination effectiveness, examining persons vaccinated prior to sexual activity and using methods to reduce potential sources of bias, can help inform vaccine policy.

Conflicts of interest

The authors have no conflicts of interest to declare.

Appendix A. Supplementary material

Supplementary data associated with this article can be found, in the online version, at https://doi.org/10.1016/j.vaccine.2018.01.057.

References

[1] Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012(Suppl. 5):F123–38.
[2] Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Poirier C, Schiffman M, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011;103(19):1444–51.
[3] Leung TF, Liu AP, Lim FS, Thollot F, Oh HM, Lee BW, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9–14 years: Results to month 12 from a randomized trial. Hum Vaccin Immunother 2015;11(7):1689–702.
[4] Iversen OE, Miranda MJ, Ulden A, Soerdal T, Lazarus E, Chokephaibulkit K, et al. Immunogenicity of the 5-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women. JAMA 2016;316(22):2411–21.
[5] Doob SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Kradjen M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013;309(17):1793–802.
[6] WHO. Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec 2014;89(43):465–91.
[7] Meites E, Kemple A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination - updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2016;65(49):1405–8.
[8] D’Addario M, Redmond S, Scott P, Egli-Gany D, Riveros-Balta AX, Henao Restrepo AM, et al. Two-dose schedules for human papillomavirus vaccine: systematic review and meta-analysis. Vaccine 2017;35(22):2892–901.
[9] Kavanagh K, Pollock KG, Potts A, Love J, Cuschieri K, Cubie H, et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer 2014;110(11):2804–11.
[10] Cuschieri K, Kavanagh K, Moore C, Bhatia R, Love J, Pollock KG. Impact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis. Br J Cancer 2016;114(11):261–4.
[11] Herweijer E, Leval A, Ploner A, Eloranta S, Simard JF, Dillner J, et al. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma. JAMA 2014;311(6):557–603.
[12] Blomberg M, Dehlendorff C, Sand C, Kjaer SK. Dose-related differences in effectiveness of human papillomavirus vaccination against genital warts: a nationwide study of 550 000 young girls. Clin Infect Dis 2015;61(5):876–82.
[13] Dominiak-Felden C, Gobbo C, Simondon F. Evaluating the early benefit of quadrivalent HPV vaccine on genital warts in Belgium: a cohort study. PLoS One 2015;10(7):e0132404.
[14] Perkins RB, Lin M, Wallington SF, Hanchate A. Impact of number of human papillomavirus vaccine doses on genital warts diagnoses among a national cohort of U.S. adolescents. Sex Transm Dis 2017;44(6):365–70.
[15] Navarro-Illana E, Lopez-Lacort M, Navarro-Illana P, Vilata JJ, Díez-Domingo J. Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain. Vaccine 2017;35(23):3342–6.
[16] Lamb F, Herweijer E, Ploner A, Sundström K, Sparén P, Arheim-Dahllöf L. Timing of two versus three doses of quadrivalent HPV vaccine and associated effectiveness against condyloma in Sweden: a nationwide cohort study. BMJ Open 2017;7(6):e015021.
[17] Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med 2013;11:227.
[18] Crowe E, Pandeya N, Brotherton JM, Dobson AJ, Kiselys S, Lambert SB, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ 2014;348:g1458.
[19] Brotherton J, Maltby S, Budd AC, Savillea M, Drennan KTA, Gertig DM. Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: Observational cohort of young women in Australia. Papillomavirus Res 2015;1:59–73.
[20] Hofstetter AM, Ompad DC, Stockwell MS, Rosenthal SL, Soren K. Human papillomavirus vaccination and cervical cytology outcomes among urban low-income minority females. JAMA Pediatr 2016;170(5):445–52.
[21] Kim J, Bell C, Sun M, Kiewer G, Xu L, McNerney M, et al. Effect of human papillomavirus vaccination on cervical cancer screening in Alberta. CMAJ 2016;188(12):E281–8.
[22] Pollock KG, Kavanagh K, Potts A, Love J, Cuschieri K, Cubie H, et al. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer 2014;111(9):1824–30.
[23] Harris S, Bennett NM, Nicolosi LM, Schauer S, Park IU, Bloch KC, et al. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States – 2008–2012. Vaccine 2015;33(13):1608–13.

Please cite this article in press as: Markowitz LE et al. Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs. Vaccine (2018), https://doi.org/10.1016/j.vaccine.2018.01.057